Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.13
-0.0400-3.42%
Post-market: 1.11-0.0200-1.77%19:53 EDT
Volume:432.11K
Turnover:490.39K
Market Cap:14.93M
PE:-1.00
High:1.17
Open:1.17
Low:1.11
Close:1.17
Loading ...

Hoth Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview

Reuters
·
03 Apr

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

PR Newswire
·
02 Apr

Hoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZ

TIPRANKS
·
02 Apr

BRIEF-Hoth Therapeutics Plans To Advance HT-ALZ Into Clinical Development

Reuters
·
02 Apr

Hoth Therapeutics Announces Positive Pre Clinical Data Ht-Alz Shows Promising Breakthrough in Alzheimer's Disease Research Acute Treatment With Ht-Alz Led to a Rapid (~15%) Reduction in Brain Interstitial Fluid aΒ Levels, Within 20 Hours

THOMSON REUTERS
·
02 Apr

Hoth Therapeutics - Plans to Advance Ht-Alz Into Clinical Development

THOMSON REUTERS
·
02 Apr

BRIEF-Hoth Therapeutics Receives Uspto Filing Receipt For Ht-001 Formulation Patent Application, Expanding Existing Patent Coverage

Reuters
·
01 Apr

Hoth Therapeutics Receives Uspto Filing Receipt for Ht-001 Formulation Patent Application, Expanding Existing Patent Coverage

THOMSON REUTERS
·
01 Apr

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

PR Newswire
·
01 Apr

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
31 Mar

Hoth Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
29 Mar

Hoth Therapeutics Inc - Files Amended Patent Claims for Ht-Kit Technology

THOMSON REUTERS
·
26 Mar

Hoth Therapeutics Inc - Initiates 4-Week Toxicity Study for Ht-Kit

THOMSON REUTERS
·
26 Mar

Hoth Therapeutics Advances Cancer Fighting Ht-Kit Program With New Patent Filing and Preclinical Study Initiation

THOMSON REUTERS
·
26 Mar

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

PR Newswire
·
26 Mar

Hoth Therapeutics to Revise Financial Statements Due to Auditing Errors

Dow Jones
·
26 Mar

Hoth Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
25 Mar

Hoth Therapeutics announces ‘positive’ results from study of HT-KIT

TipRanks
·
19 Mar

Hoth Therapeutics Announces Positive Preclinical Results for Ht-Kit in Aggressive Cancer Gastrointestinal Stromal Tumors (Gist). Ht-Kit Triggered Significant Tumor Cell Death as Early as 24 Hours Post-Treatment

THOMSON REUTERS
·
18 Mar

Hoth Therapeutics Inc: New Data Demonstrates Significant Reduction in Tumor Growth

THOMSON REUTERS
·
18 Mar